Could a diabetes drug help obese patients get better knee replacements?
NCT ID NCT06807970
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests whether the weight-loss drug semaglutide can improve outcomes for obese patients waiting for total knee replacement. 54 participants will receive the drug for 48 weeks before and after surgery. The goal is to see if weight loss reduces pain and complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide (a glucagon-like peptide-1 receptor agonist, GLP-1 RA)
What this could lead to
If it works, this could show that weight loss with semaglutide before knee replacement reduces pain and complications in obese patients.
What could go wrong
This is a very early, small trial (54 people) with no results yet. The drug may not improve outcomes and can cause side effects like nausea or pancreatitis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS (OA) OF THE KNEE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••